Scheibye-Knudsen Lab
Background
The study, consisting of over 1.4 billion prescriptions, found that a number of prescription drugs were highly associated with longer life- and health-span in long-live populations. Here, we present a unique investment opportunity. We seek to validate these observations through a series of carefully conducted wet lab experiments. If successful, this work could result in the repurposing of several FDA-approved therapeutics for the purpose of extending human lifespan, at a lower cost and over faster timelines than conceivably possible with de novo drug discovery. This unique investment opportunity allows savvy longevity investors the chance to own a share of the potential intellectual property generated from these studies, and in turn, a potential share in the future of life extension.
Aims, Hypothesis & Results
The global elderly population is projected to substantially increase throughout the 21st century. By the year 2100 a fifth of the total world population will be aged 65 or older posing a serious socioeconomic challenge to societies world-wide. Interventions that ensure healthy aging are therefore of critical importance.
Timeline
Pre-Clinical Studies 1: Testing in Fruit Flies and Human Cells
Required Funding: $500,000
Status: Ongoing
Duration: 24 Months
Testing the identified drugs ability to attenuate features of aging in a controlled laboratory setting. Here, we will test the molecules in human cells and in the animal model drosophila melanogaster (fruit flies). We are testing the drugs in human cells to rapidly understand how the molecules affect human cellular aging. Fruit flies are used extensively in biomedical research and particular aging research as they have a short lifespan of about 60 days.
VitaDAO Board Evaluation Writeup
This program focuses on testing and developing three of these small molecules as possible interventions in aging. Specifically, we will test the drugs on human cell cultures and in various animal models. Importantly, the current anti-aging market stands at 200 billion USD, even without a single scientifically proven treatment. Our molecules targets this specific market with the aim of letting everyone live healthier, happier and longer lives.
The vote has passed, the decision is made: Morten Scheibye-Knudsen Lab will be the first research organisation to fund their longevity research via an IPNFT. This historic moment needs to be celebrated properly!
Lab-Tour with Founder Morten
Take a quick look at Scheibye-Knudsen Lab in Copenhagen, where the first longevity research project to be funded by VitaDAO is prepared.
The Flies are ready! Scheibye-Knudsen Lab Update
A first intro by the team of The Scheibye-Knudsen Lab, one of the first research project getting funded by VitaDAO.
Discover more projects & initiatives
About VitaDAO
